Clinical Trial Update: Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating concomitant apremilast for active rheumatoid arthritis in patients on TNF inhibitors and methotrexate has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• OTEZLA (apremilast)

Snippet

Sponsor: Stanford University | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: WITHDRAWN